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Abstract
Preeclampsia (PE) is a pregnancy-specific hypertensive syndrome characterized by excessive maternal immune system
activation, inflammation, and endothelial dysfunction. Toll-like receptor (TLR) 3 activation by double-stranded RNA (dsRNA)
and TLR7/8 activation by single-stranded RNA (ssRNA) expressed by viruses and/or released from necrotic cells initiates
a pro-inflammatory immune response; however it is unknown whether viral/endogenous RNA is a key initiating signal that
contributes to the development of PE. We hypothesized that TLR3/7/8 activation will be evident in placentas of women with
PE, and sufficient to induce PE-like symptoms in mice. Placental immunoreactivity and mRNA levels of TLR3, TLR7, and TLR8
were increased significantly in women with PE compared to normotensive women. Treatment of human trophoblasts with
the TLR3 agonist polyinosine-polycytidylic acid (poly I:C), the TLR7-specific agonist imiquimod (R-837), or the TLR7/8 agonist
CLO97 significantly increased TLR3/7/8 levels. Treatment of mice with poly I:C, R-837, or CLO97 caused pregnancy-
dependent hypertension, endothelial dysfunction, splenomegaly, and placental inflammation. These data demonstrate that
RNA-mediated activation of TLR3 and TLR7/8 plays a key role in the development of PE.
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Introduction
Preeclampsia (PE), a condition which affects ,10% of
pregnancies, can lead to significant morbidity and mortality in
both the mother and the fetus and can also increase the risk of
future cardiovascular disease in the mother [1–4]. PE is defined as
hypertension and proteinuria at or after 20 weeks gestation and is
associated with endothelial dysfunction and premature birth. The
placenta is a key player in the etiology of PE as symptoms typically
abate after placental delivery.
While there are many theories regarding the causes of PE, the
exact origins of the disorder remain elusive. Proposed causes
include inadequate trophoblast invasion, angiogenic imbalance,
and improper adaptation of the immune system to the state of
pregnancy [5,6]. During pregnancy, the immune system must
tolerate a half-foreign fetus, while still defending the body from
pathogens. Many groups have hypothesized that an inadequate
tolerance of the fetus by the maternal immune system may
manifest as PE [7–10]. This hypothesis is strengthened by the fact
that pregnant women who had a previous pregnancy with the
same partner are less likely to develop PE than nulliparous women
or women conceiving for the first time with a new partner. This
effect is presumably due to a protective effect by previous contact
with antigens [11–13]. However, the molecular mechanism by
which the immune system contributes to the etiology of PE
remains undefined.
The immune system responds to not only foreign pathogens but
also endogenous markers of cellular damage. These ‘‘danger
signals’’ or pathogen-associated molecular patterns (PAMPs)
include RNA, DNA, heat shock proteins, uric acid, tumor necrosis
factor, and others [6]. Sources of these PAMPs include viral and
bacterial infections and tissue necrosis. As the danger theory
relates to pregnancy, these factors are not present during normal
pregnancy, and thus the immune system is not activated
excessively. However, in PE danger signals may be present leading
to activation of their specific innate immune receptors, TLRs,
excessive immune system activation, and inflammation via nuclear
factor-kB (NF-kB) and interferons [14–20].
Bacterial components (LPS) acting on TLR2 and TLR4 have
been implicated in the etiology of some forms of PE [21–23];
however whether viral/endogenous RNA plays a role in PE is
unclear. Epidemiological studies have indicated that a primary viral
infection during pregnancy is strongly associated with PE [24–27].
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Excessive tissue necrosis and apoptosis from abnormal implantation
or spiral artery remodeling at the feto-maternal interface may also
cause the release of double-stranded RNA (dsRNA) and single-
stranded (ssRNA) [28–31]. Therefore, we evaluated the roles of
TLR3, which responds to dsRNA, and TLRs 7 and 8, which
respond to ssRNA, in the development of PE. These TLRs are
highly expressed in a variety of innate immune cells, vascular
endothelial cells, and other cells at the feto-maternal interface
including trophoblasts [31–35]. We hypothesized that activation of
TLR3/7/8 is increased in placentas of women with PE and is
sufficient to induce PE-like symptoms in mice.
Results
Placental TLR3/7/8 Activation and Inflammation in
Women with PE
Placental tissue obtained from women delivering in 2010 was
acquired from the Department of Pathology at Texas A&MHealth
Science Center/Scott & White Memorial Hospital. Anonymized
patient characteristics were obtained in a retrospective manner and
are presented in Table 1. Placental tissue and chart data were
obtained for 13 pregnant (P) and 17 PE women diagnosed by the
presence of hypertension and proteinuria. Some women in the
pregnant (P) control group were clinically diagnosed with chor-
ioamnionitis, chronic hypertension, proteinuria without hyperten-
sion, or premature rupture ofmembranes. There were no significant
differences in age, body weight, or body mass index between the P
and PE groups (Table 1). In addition to the hypertension and
proteinuria, there was a significant decrease in gestational age,
placental weight, and baby weight in PE women compared to P
women (Table 1).
To examine activation of TLR3/7/8 in placentas from P and
PE women, we performed immunohistochemistry as well as
measures of mRNA levels. Placentas from PE women had
increased immunoreactivity of TLR3, TLR7, and TLR8 which
was maximal in the outer syncytiotrophoblasts but was also present
in the inner cytotrophoblasts (Figure 1A). Placental mRNA levels
of TLR3, TLR7, and TLR8 were also increased significantly in
women with PE compared to P women (Figure 1B).
TLR3/7/8 Activation in Human Trophoblasts
Next we determined whether direct activation of TLR3, TLR7,
and TLR7/8 could occur in human cytotrophoblasts. Treatment
of cytotrophoblasts with the TLR3-specific agonist poly I:C for 6,
24, and 48 hours significantly increased TLR3 protein levels at 6
and 24 hours which returned to baseline at 48 hours (Figure 2A).
The TLR7-specific agonist R-837 significantly increased TLR7
protein levels ,3-fold at 6 hours which returned to basal levels at
24 hours and decreased below basal levels at 48 hours (Figure 2B).
CLO97, which activates both TLR7 and TLR8, significantly
increased both TLR7 and TLR8 ,2–3-fold at 6 hours while both
returned to basal levels at 24 hours and decreased below basal
levels at 48 hours (Figure 2C). Taken together, these data
demonstrate that direct activation of TLR3/7/8 can occur in
human trophoblasts, which leads to inflammation and immune
cell activation via well-known TLR signaling pathways.
TLR3/7/8 Activation in Pregnant Mice
We next examined whether TLR3 or TLR7/8 activation in
mice could induce placental inflammation and PE-like symptoms.
Pregnant mice were treated with either vehicle, poly I:C, R-837,
or CLO97 given by intraperitoneal injection on gestational days
13, 15, and 17 followed by euthanization on gestational day 18.
Eighty four inflammation-related genes were analyzed by quan-
titative Real-Time Polymerase Chain Reaction (qRT-PCR) and
those that were significantly altered in all 3 groups are presented in
Table 2. Consistent across all 3 groups of mice, the mRNA levels
of 17 genes were increased significantly in placentas of mice
following TLR3, TLR7, or TLR7/8 activation compared to
vehicle-treated control mice and these included several pro-
inflammatory chemokines, cytokines, receptor/ligands, and tran-
scription factors (Table 2). The mRNA levels of only 2 genes were
decreased significantly in the placentas of all 3 groups, osteopontin
(Spp1) and interleukin (IL)-18.
Treatment of pregnant mice with poly I:C via intraperitoneal
injection lead to a significant increase in placental TLR3 gene and
protein levels (Figure 3A). Treatment of pregnant mice with the
TLR7-specific agonist R-837 significantly increased placental
TLR7 mRNA and protein levels while having no effect on
TLR8 expression (Figure 3B). Similarly, treatment of pregnant
mice with the TLR7/8 agonist CLO97 significantly increased
both TLR7 and TLR8 mRNA and protein levels (Figure 3B).
We then determined whether TLR3 or TLR7/8 activation and
subsequent placental inflammation was sufficient to induce PE-like
symptoms in mice. In non-pregnant mice, activation of TLR3,
TLR7, or TLR7/8 with poly I:C, R-837, or CLO97, respectively,
had no effect on systolic blood pressure (Figure 4A). However, in
pregnant mice these agonists all significantly increased systolic
blood pressure at gestational day 17 compared to vehicle-treated
controls (P: 10462 mm Hg, P+TLR3: 14363 mm Hg, P+TLR7:
13361 mm Hg, P+TLR7/8: 12961 mm Hg; all p,0.05 vs. P;
Figure 4A). These data suggest that TLR3/7/8 activation causes
hypertension only during pregnancy.
Next, we examined whether TLR3/7/8 activation in mice
elicits endothelial dysfunction similar to that seen in women with
PE. In non-pregnant mice, treatment with poly I:C, R-837, or
CLO97 had no effects on aortic relaxation responses induced by
acetylcholine (Figure 4B). However, TLR3, TLR7, or TLR7/8
activation during pregnancy caused a significant decrease in
maximal aortic acetylcholine-induced relaxation responses (P:
7864%, P+TLR3: 3963%, P+TLR7: 3463%, P+TLR7/8:
5063%; all p,0.05 vs. P; Figure 4B). To determine whether
TLR3 or TLR7/8 activation caused smooth muscle dysfunction,
we measured aortic relaxation responses to the nitric oxide donor
sodium nitroprusside. Figure 4C demonstrates that TLR3, TLR7,
or TLR7/8 activation had no effect on sodium nitroprusside-
induced aortic relaxation in either non-pregnant or pregnant mice.
Taken together, these data show that TLR3/7/8 activation causes
endothelial dysfunction only during pregnancy.
Table 1. Data for pregnant and preeclamptic patients.
Pregnant
(n=13)
Preeclampsia
(n=17)
Age (years) 24.661.2 26.261.1
SBP (mm Hg) 13267 16265*
DBP (mm Hg) 7164 9462*
Weight (pounds) 195621 19168
BMI 3464 3362
Gestational Age (months) 37.860.7 30.761.1*
Placental weight (grams) 490629 26763*
Baby weight (grams) 2,8866186 1,5496225*
Data presented as mean 6 SEM. SBP = systolic blood pressure, DBP =diastolic
blood pressure, BMI = body mass index. *p,0.05 vs. pregnant.
doi:10.1371/journal.pone.0041884.t001
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In addition to hypertension and endothelial dysfunction, we
examined whether TLR3/7/8 activation during pregnancy
caused other PE-like symptoms. TLR3 or TLR7 activation with
poly I:C or R-837 caused a significant increase in urinary protein
excretion, however TLR7/8 activation with CLO97 unexpectedly
had no effect (P: 5262 mg/dL, P+TLR3: 89610 mg/dL,
Figure 1. Increased TLR3/7/8 immunoreactivity and mRNA levels in placentas of women with preeclampsia. (A) Representative images
where brown staining indicates immunoreactivity and blue indicates hematoxylin staining of nuclei in placentas from pregnant (P, n = 13, top panels)
and preeclamptic (PE, n = 17, bottom panels) women. (B) mRNA levels of TLR3, TLR7, and TLR8 in placentas from PE and P women. Results are
expressed as mean + SEM. *p,0.05 vs P.
doi:10.1371/journal.pone.0041884.g001
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P+TLR7: 9067 mg/dL, P+TLR7/8: 4663 mg/dL; Figure 5A).
TLR3/7/8 activation during pregnancy had no effect on body
weight (Figure 5B), however poly I:C, R-837, and CLO97 all
caused splenomegaly, supporting a state of excessive inflammation
and immune system activation during pregnancy (spleen weight/
body weight-P: 3.060.1 mg/g, P+TLR3: 5.760.3 mg/g,
P+TLR7: 4.660.3 mg/g, P+TLR7/8: 5.160.3 mg/g; all
p,0.05 vs. P; Figure 5C).
Lastly, we determined the effects of TLR3/7/8 activation
during pregnancy on fetal and placental development. Poly I:C,
R837, or CLO97 had no effects on total litter weight (determined
by weighing intact uterine horn containing pups, placentas, and
Figure 2. TLR3/7/8 activation in human trophoblasts. Representative images and densitometric analyses of TLR3, TLR7, and TLR8 protein levels
from 4 independent experiments for (A) the TLR3 agonist poly I:C, (B) the TLR7 agonist R837, and (C) the TLR7/8 agonist CLO97. Results are expressed
as mean + SEM. *p,0.05 vs baseline.
doi:10.1371/journal.pone.0041884.g002
Table 2. Inflammation-related genes significantly (p,0.05 vs. P) altered in placentas of mice treated with a TLR3, TLR7, or TLR7/8
agonist during pregnancy.
Gene Symbol P vs. P+TLR3 (Fold change) P vs. P+TLR7 (Fold change) P vs. P+TLR7/8 (Fold change)
Chemokines
Ccl5 (RANTES) 25.6264.65 10.3862.30 5.0161.44
Ccr3 2.1460.85 2.1360.65 2.4860.73
Ccr10 2.9561.07 2.3260.67 2.6860.47
Spp1 23.8660.68 23.2960.68 23.0060.63
Cytokines
IL2 2.2760.04 2.6760.34 2.2360.71
IL4ra 4.2560.72 5.1861.21 4.2260.63
IL6 2.2160.16 2.7260.16 2.8360.63
IL17A 2.2160.54 2.6760.33 2.2360.54
IL18 22.0960.58 22.2360.84 22.3860.26
IL27 2.8160.44 3.8160.71 2.8760.71
IFNg 2.9760.71 2.8760.54 2.5660.79
TNF 2.0360.71 2.5960.30 2.2460.55
Receptors/Ligands
CD4 3.0760.40 4.9860.53 5.7461.12
CD40 2.0660.55 5.4060.65 4.0860.96
CD40ligand 2.2160.59 2.6760.23 2.2360.25
Transcription Factors
GATA3 2.4160.57 2.7560.41 5.0661.65
Junb 2.5160.51 10.3862.30 4.8261.59
NFkB 4.6860.65 4.0260.48 4.4660.85
Stat4 2.2160.49 2.6760.88 2.2360.62
P =pregnant, P+TLR3 = pregnant+TLR3 agonist poly I:C, P+TLR7 = pregnant+TLR7 agonist R837, P+TLR7/8 = pregnant+TLR7/8 agonist CLO97. All p,0.05 vs. P, n.3 in
each group.
doi:10.1371/journal.pone.0041884.t002
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amniotic fluid) which were ,7.5 g in all 4 groups (Figure 5D) or
on the number of pups/litter which were all around ,8–9 pups/
litter (Figure 5E). However, poly I:C, R-837, and CLO97 all
caused a significant increase in fetal demise assessed as the mean
number of malformed or resorbed pups/litter on day 18 of
pregnancy (P: 0.260.2, P+TLR3: 1.660.8, P+TLR7: 1.060.3,
P+TLR7/8: 0.960.1; all p,0.05 vs. P; Figure 5E).
Figure 3. Placental TLR3/7/8 activation in pregnant mice. Fold-increase and representative images and densitometric analyses of TLR3, TLR7,
and TLR8 mRNA and protein levels, respectively, from 4 independent experiments in mice treated with (A) the TLR3 agonist poly I:C and (B) the TLR7
agonist R837 and the TLR7/8 agonist CLO97. Results are expressed as mean + SEM. *p,0.05 vs P.
doi:10.1371/journal.pone.0041884.g003
Figure 4. TLR3/7/8 activation in mice caused pregnancy-dependent hypertension and endothelial dysfunction. Measures of (A)
systolic blood pressure, (B) aortic endothelium-dependent relaxation induced by acetylcholine, and (C) aortic endothelium-independent relaxation
induced by sodium nitroprusside in non-pregnant (top panels) and pregnant (bottom panels) mice treated with TLR3 agonist poly I:C, the TLR7
agonist R837, or the TLR7/8 agonist CLO97. Results are expressed as mean 6 SEM and the n is given in parentheses. *p,0.05 vs P.
doi:10.1371/journal.pone.0041884.g004
TLR3/7/8 and Preeclampsia
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Discussion
The initiating factors that cause PE in ,10% of all pregnancies
remain elusive however placental dysfunction and inflammation
play key roles. Here we present a unifying hypothesis that these, in
some women, are caused by RNA-mediated activation of placental
TLR3 and TLR7/8 leading to PE. Supportive evidence comes
from our findings that TLR3/7/8 immunoreactivity and mRNA
levels are increased significantly in placentas of women with PE,
that direct activation of TLR3/7/8 occurs in human trophoblasts,
and that TLR3/7/8 activation in mice causes placental in-
flammation, splenomegaly, fetal demise, and pregnancy-depen-
dent hypertension and endothelial dysfunction.
Women diagnosed with PE had a significant increase in
placental immunoreactivity and mRNA levels of TLR3, TLR7,
and TLR8 compared to normotensive women. A previous study
also reported increased TLR3 staining in the trophoblast, vascular
endothelium, and stroma of PE women, however TLR7 and
TLR8 staining were not examined [36]. Even though our
normotensive P group consisted of women with chorioamnionitis,
chronic hypertension, proteinuria without hypertension, or pre-
mature rupture of membranes, there were no placentas in this
group that had increased levels of TLR3. In the P group, only 3/
13 placentas for TLR7 and 6/13 placentas for TLR8 exhibited
increased levels of these receptors. There was no apparent trend
between significant placental TLR activation and clinical in-
dication in the P group. For instance, of the 6 women with
chorioamnionitis none had increased levels of TLR3, only 1 had
increased levels of TLR7, and 2 for TLR8. Interestingly, 2 women
had increased levels for both TLR7 and TLR8 but not TLR3.
One woman was a smoker having her 3rd child and the other
experienced pre-term rupture of membranes which may have
resulted in an acute release of ssRNA. In the PE group, only 4/17
placentas for TLR3 and 2/17 placentas for TLR7 had decreased
levels of these receptors while no placentas from PE women had
decreased levels of TLR8. These data suggest that significant
placental activation of TLR3, TLR7, and TLR8 together is highly
associated with PE, but whether these occur prior to the
development of PE in women remains to be determined.
Trophoblasts are the main cell type at the feto-maternal
interface and exert many functions necessary for normal
pregnancy including the regulation of spiral artery remodeling
and angiogenesis as well as pathogen sensing and immune system
signaling. Trophoblasts express numerous TLRs including TLR3,
TLR7, and TLR8 and are able to secrete NF-kB-derived pro-
inflammatory chemokines and cytokines [19,31,32,37–41]. To
determine whether TLR3/7/8 activation occurs in trophoblasts,
we treated human trophoblasts with agonists for TLR3, TLR7, or
TLR7/8. All 3 agonists were able to rapidly increase protein levels
of their respective TLR with the peak being 6 hours. Together
these findings suggest that persistent TLR3/7/8 activation (i.e.,
chronic elevated levels of dsRNA and ssRNA) in trophoblasts may
be the cause of the placental dysfunction and inflammation seen in
PE.
If placental TLR3/7/8 activation is sufficient to cause PE, then
treatment of mice with TLR3/7/8 agonists should elicit endothe-
lial dysfunction, proteinuria, and hypertension only if the animal is
pregnant. We have previously reported that TLR3 activation with
poly I:C in rats and mice causes systemic inflammation in both
pregnant and non-pregnant animals, however only pregnant
animals developed hypertension, proteinuria, and endothelial
dysfunction [42–44]. In the current study, we confirm these
findings.
Additionally, 19 placental genes that are significantly altered in
poly I:C-treated mice are also significantly altered in mice treated
with either a TLR7 or TLR7/8 agonist. The 17 placental genes
Figure 5. TLR3/7/8 activation in pregnant mice caused PE-like symptoms. Measures of (A) urinary protein concentration, (B) maternal body
weight, (C) spleen weight/body weight, (D) litter weight, and (E) number of total pups/litter and fetal demise/litter in pregnant mice treated with the
TLR3 agonist poly I:C, the TLR7 agonist R837, or the TLR7/8 agonist CLO97. Results are expressed as mean + SEM and n=9 in each group. *p,0.05
vs. P.
doi:10.1371/journal.pone.0041884.g005
TLR3/7/8 and Preeclampsia
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41884
that were significantly increased in all 3 groups are known to play
key roles in the inflammatory response. PE women have elevated
levels of interferon-c, tumor necrosis factor-a, IL-17A, IL-6, and
CD-40/CD-40 ligand [45–47], all genes that were significantly
increased in the placentas of TLR3, TLR7, and TLR7/8 agonist-
treated mice. The 2 placental genes that were decreased in all 3
groups interestingly have pro-inflammatory chemokine/cytokine
roles. However, osteopontin, which increases throughout normal
gestation, is also an extracellular matrix protein that plays a role in
cell-cell and cell-matrix interactions [48]. It is possible that this
decrease in placental osteopontin levels may contribute to the
disorganization of placental cells evident in PE [49]. Additionally,
osteopontin and IL-18, the other placental gene decreased in
TLR3/7/8 agonist-treated mice, both potentiate T helper cell
type 1 immune responses [48], whereas IL-2, IL-6, and IL-17A, all
significantly increased in placentas of TLR3/7/8 agonist-treated
mice, potentiate a T helper cell type 17 immune response
characteristic of PE [46,47]. More studies are needed to determine
the temporal and functional effects of altered placental gene
expression including the placental downregulation of osteopontin
and IL-18 and their role in the development of PE.
Similar to TLR3 activation, TLR7/8 activation during pregnan-
cy in mice caused pregnancy-dependent hypertension, endothelial
dysfunction, splenomegaly, and an increased incidence of fetal
demise. Importantly, blood pressure and endothelial function were
not affected by TLR7 or TLR7/8 activation in non-pregnant mice.
These findings demonstrate that placental activation of TLR3/7/8
is crucial for the development of endothelial dysfunction and
hypertension during pregnancy. Fetal demise in mice likely results
from placental dysfunction and decreased placental perfusion and
somewhat mimics intra-uterine growth restriction, commonly seen
in women with PE. We reported that TLR3 ligation in mice
increased the incidence of fetal demise, and almost identical results
were seen in TLR7 as well as TLR7/8 agonist-treated mice. A
previous study found that rats treated with the TLR4 agonist
lipopolysaccharide at gestational day 14.5 also exhibited increased
fetal demise as a result of decreased placental perfusion [50].
Although TLR3 and TLR7 activation induced proteinuria, TLR7/
8 activation did not. Some studies have demonstrated that not only is
TLR8 functional in mice, but that it may suppress TLR7-mediated
effects. Demaria and colleagues reported thatTlr82/2mice develop
autoimmune glomerulonephritis due to excessive TLR7 expression
and activation, and that this was attenuated in double Tlr72/
2/Tlr82/2 mice [51]. Unfortunately, urinary protein concentra-
tions were not measured, but their findings together with our results
suggest that the stimulation of renal, not placental, TLR8 may have
a protective effect on renal function. Nonetheless, excessive
activation of placental TLR7/8 is sufficient to induce pregnancy-
dependent hypertension and endothelial dysfunction similar to that
induced by TLR3 activation. However, examination of the role of
TLR8 signaling in the mouse and how this might contribute to the
development of PE-like symptoms is needed. If TLR8 signaling in
mice is found to be non-functional, then it is likely that the
mechanisms that cause PE inCLO97-treatedmice are due to TLR7
activation, similar to that of R837-treated mice.
Placental activation of TLR3/7/8 by dsRNA and ssRNA could
arise from latent viruses, viruses acquired during gestation, as well
as excessive cellular necrosis/apoptosis resulting from aberrant
implantation, placentation, placental hypoxia, and/or trophoblast
invasion [28,30]. Additionally, heterologous RNA released from
necrotic cells or associated with in vitro transcription was reported
to be an endogenous ligand for TLR3 [52]. While extracellular
heterologous RNA levels are normally low, high levels of
extracellular heterologous RNA are evident at sites of inflamma-
tion and tissue necrosis, similar to that of dsRNA and ssRNA [52].
Whether heterologous RNA can also activate TLR7/8 is unknown
currently. While TLR3 signals through Toll-IL-1 receptor-
domain-containing adaptor inducing interferon-b (TRIF), TLR7
and TLR8 signal through myeloid differentiation marker 88
(MyD88). However, both pathways converge to activate NF-kB
leading to the transcription of numerous pro-inflammatory
chemokines and cytokines. Inflammation is necessary for placental
and fetal development, however excessive inflammation resulting
from persistent placental TLR3/7/8 activation may explain the
increase in circulating pro-inflammatory cytokines evident in
women with PE.
Here we demonstrate that TLR3, TLR7, and TLR8 levels are
significantly increased in placentas from PE women at delivery,
but it is unknown if this occurs prior to the onset of PE symptoms
in women. Given our findings that TLR3, TLR7, or TLR7/8
activation was sufficient to produce pregnancy-dependent hyper-
tension and endothelial dysfunction in mice, we hypothesize that
excessive TLR3/7/8 activation initiates the symptoms of PE in
women, however prospective studies and earlier measures are
needed. Our results suggest that TLR3, TLR7, and TLR8 play
a significant role in the development of PE and may be potential
therapeutic targets to diminish the severity of PE symptoms in
women.
Materials and Methods
Ethics Statement
The research study involving human placental samples was
reviewed by the Texas A&M Health Science Center/Scott and
White Institutional Review Board (Federal Assurance
#FWA00003358, IRB Registration #IRB00000706) prior to
initiation, and all patient identifiers were removed from sample
and patient data. The IRB approved the study as exempt from
requiring patient consent according to category 45 CFR
46.101(b)(4) (Project # 100581, 12/27/2010) and the samples
were available from an archive maintained by the Department of
Pathology for research purposes. All procedures performed in mice
were approved by the Texas A&M Health Science Center/Scott
and White Memorial Hospital IACUC in accordance with the
NIH Guide for the Care and Use and Care of Laboratory Animals.
Patient Data and Human Placental
Immunohistochemistry and mRNA Levels
Paraffin-embedded blocks of placental tissue were obtained
from P (n= 13) and PE (n = 17) women who delivered between
March and September 2010 by the Texas A&M Health Science
Center/Scott and White Memorial Hospital Department of
Pathology. Twenty slides from each block (5 mm thick) were used
for immunohistochemistry. The samples were first deparaffinized
and then antigen retrieval was performed. This was followed by
quenching of endogenous peroxidase using 3% hydrogen peroxide
for 5 minutes. The slides were then blocked with appropriate
diluted blocking serum for 20 minutes and were stained with
antibodies using the following concentrations: TLR3 at 1:100
(Imgenex; San Diego, CA), TLR7 at 1:500 (Imgenex), and TLR8
at 1:500 (Imgenex) for 1 hour at room temperature. Incubation
with biotinylated secondary antibody for 45 minutes was followed
by streptavidin-peroxidase for 10 minutes, and then developed
with 3,39-diaminobenzidine (DAB). Hematoxylin was used as
a counterstain (blue) to denote cell nuclei and slides incubated with
secondary antibody only served as negative controls. Additionally,
formalin-fixed, paraffin-embedded sections of placental tissue
(10 mm thick) were obtained from both P and PE patients for
TLR3/7/8 and Preeclampsia
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qRT-PCR reactions. First, paraffin was removed with deparaffi-
nization solution by incubating at 56uC for 3 minutes followed by
slow cooling to room temperature. RNA was isolated using
a RNeasy FFPE kit (Qiagen; Valencia, CA) following the
manufacturer’s protocol. cDNA was prepared from 500 gg
RNA and was further pre-amplified using a RT2 PreAmp cDNA
synthesis kit (Qiagen) per the manufacturer’s protocol. Human
primers for TLR3 (SABiosciences), TLR7 (SABiosciences), and
TLR8 (Origene) were used for qRT-PCR and were performed
using SYBR Green (SABiosciences, Valencia, CA). Amplification
of the genes of interest and the housekeeping control gene
GAPDH was done in duplicate from each sample and a no
template control. The relative fold change in expression level
compared to placentas from P women was determined using the 2
(2DDCt) method.
Tissue Culture
Human SGHPL-4 cytotrophoblasts [28,53], obtained from
Professor Guy Whitley (St. George’s, University of London, UK),
were cultured in Ham’s F-10 media supplemented with 10% fetal
bovine serum, penicillin G (100 units/ml), streptomycin (100 mg/
ml) and 2 mM l-glutamine. Cells were incubated at 37uC in a 5%
CO2 incubator and serum starved for 24 hours prior to treatment
with either vehicle, poly I:C (2 mg/ml), R837 (10 mg/ml), or
CL097 (25 mg/ml). Cells were lysed after 6, 24, or 48 hours of
treatment and protein was isolated subsequently for the immuno-
blotting studies described below.
Mouse Studies
Male C57BL/6J mice, used for mating purposes only, and
female C57BL/6J mice were purchased from Jackson Laborato-
ries (Bar Harbor, ME). Female mice, aged 10–12 weeks, were
grouped as pregnant (P), pregnant treated with poly I:C
(P+TLR3), pregnant treated with R837 (P+TLR7), or pregnant
treated with CL097 (P+TLR7/8). Non-pregnant mice served as
controls for each of the 4 groups (C, C+TLR3, C+TLR7,
C+TLR7/8). P mice were treated with vehicle (phosphate buffered
saline), P+TLR3 mice were treated with poly I:C (20 mg/kg),
P+TLR7 mice were treated with R837 (4 mg/kg), and P+TLR7/8
mice were treated with CL097 (20 mg/kg) via intraperitoneal
injections on days 13, 15, and 17 of gestation while non-pregnant
mice were given the same injections on corresponding days. Tail-
cuff systolic blood pressures (IITC, Inc.; Woodland Hills, CA)
were measured at baseline and on day 13 and day 17, prior to
injections, as described previously [42]. Mice were weighed and
then sacrificed on day 18 of pregnancy or corresponding day in
non-pregnant mice and blood, urine, and tissues were collected.
Spleens were excised and weighed and the spleen weight/body
weight ratio (mg/g) was calculated. The entire intact uterine horn
containing pups, placentas, and amniotic fluid was excised and
weighed. Pups and placentas were then dissected out and counted,
and the number of pups experiencing fetal demise due to
resorption or malformations was also counted. Protein concentra-
tions in urine obtained on day 18 were measured using the
pyrogallol red method (Total Protein Kit, Micro Pyrogallol Red
Method, Sigma) as described previously [42]. Relaxation re-
sponses were assessed in isolated endothelium-intact aortic rings
(2 mm) obtained from mice on day 18 as described previously
[42]. Briefly, aortas were mounted on stainless steel pins in
a myograph (Danish Myo Technology; Ann Arbor, MI) and were
warmed to 37uC, oxygenated with 95% O2/5% CO2, and set at
a passive tension of 0.75 g of force. Following examination of
viability, vessels were contracted with an EC70 concentration of
phenylephrine (1 mM) followed by cumulative concentrations of
the endothelium-dependent dilator acetylcholine. Vessels were
then washed until passive tension returned to baseline followed by
phenylephrine-induced contraction and the addition of cumulative
concentrations of the endothelium-independent dilator sodium
nitroprusside. Concentrations-response curves were generated
based on the percent of relaxation from the phenylephrine-
induced contraction.
Immunoblotting
Human trophoblasts and mouse placentas were lysed/homog-
enized in the presence of protease and phosphatase inhibitors in
lysis buffer (Cell Signaling; Boston, MA). Electrophoresis was
performed on 4–12% sodium dodecyl sulfate polyacrylamide gels
and transferred onto nitrocellulose membranes (Millipore; Bill-
erica, MA). Western blot analyses were performed as described
previously [42] using the following primary antibodies: TLR3
1:1,000 (Imgenex, San Diego, CA), TLR7 1:500 (Ebioscience; San
Diego, CA), and TLR8 1:500 (Imgenex), and beta-actin 1:10,000
(Sigma; St. Louis, MO). The secondary antibodies consisted of
anti-rabbit and anti-mouse IgGs conjugated to Alexa-Fluor 680 or
IRDye 800 (LI-COR Biosciences; Lincoln, NE). Infrared visual-
ization was used followed by densitometric analyses using the
provided software (Odyssey System, LI-COR Biosciences). The
ratio of the densitometry of the TLR band to the actin band was
calculated and then expressed as a % of untreated control
trophoblasts or P mice.
qRT-PCR
RNA from mouse placentas was isolated using an RNEasy Kit
(Qiagen; Valencia, CA). An iScript Synthesis Kit (Bio-Rad;
Hercules, CA) was used to perform reverse transcription using
1 mg total RNA to prepare cDNA, which was analyzed via qRT-
PCR reactions performed using a SYBR Green System (Qiagen)
per the manufacturer’s instructions. The RT2 Profiler Th1-Th2-
Th3 PCRarray from SABiosciences (Qiagen) was used and
consisted of 84 genes involved in immune cell activation. The 2
(2DDCt) method was used to determine the fold change in RNA
expression compared to placentas from P mice.
Statistical Analyses
Results are presented as mean 6 standard error of the mean.
The Student’s t-test was used to compare measures between P and
PE women. For measurements examined in human trophoblasts
and pregnant mice, a one-way analysis of variance was used
followed by the Student’s-Newman-Keuls post hoc test when
necessary. Temporal changes in mice for systolic blood pressure
were analyzed by a repeated-measures analysis of variance
followed by the Student’s-Newman-Keuls post hoc test when
necessary. The significance level was 0.05.
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